Cargando…
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN(®), induces robust humoral and cellular immunity in mice and non-human primates
At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving bo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438359/ https://www.ncbi.nlm.nih.gov/pubmed/36056015 http://dx.doi.org/10.1038/s41541-022-00528-3 |